PositiveID's Chief Science Officer Discusses Company's Detection of Flu Virus on its FireflyDX Prototype in Interview with
February 05 2018 - 8:00AM
InvestorsHub NewsWire
PositiveID's Chief
Science Officer Discusses
Company's Detection of
Flu Virus on its
FireflyDX Prototype in Interview
with CEOLIVE.TV
Dr. Kimothy Smith discusses
importance of point of care/point of need
detection during flu season
DELRAY BEACH, FL
-- February
5,
2018 -- InvestorsHub NewsWire -- PositiveID Corporation (the
"Company") (OTC:
PSID), a life
sciences company
focused on detection and diagnostics,
and its
ExcitePCR subsidiary announced
today
that
Chief
Science Officer, Dr. Kimothy Smith, discussed the
Company's successful
detection
of influenza virus on its FireflyDX real-time
polymerase chain
reaction ("PCR") breadboard prototype
system ("prototype
system") in a new interview
with CEOLIVE.TV. The interview
can be viewed
here.
In the
interview, Smith
described
the
Company's successful detection of several types
of the influenza virus
on its FireflyDX prototype system and discussed the
importance of point-of-need detection for
flu and other pathogens. Smith
also
detailed
the
ease of
use of the Company's FireflyDX prototype system and discussed how
FireflyDX could enable faster, more
accurate diagnosis at the
point of care or
point of need
("POC/PON"). Five different flu
virus assays (Type A; Type B; H3N3; H7N1; and, H5N1) were tested on
the FireflyDX prototype system in the lab.
PositiveID and
ExcitePCR are developing the
FireflyDX
family of
products in both portable and
handheld forms, to provide accurate, rapid pathogen detection using
real-time PCR in less than 30 minutes, with minimally trained
personnel and at a lower cost than existing systems. Current
solutions for accurately identifying potential pathogens and
bio-threats, especially at the POC/PON, can sometimes take as long
as several hours to several days to provide results, dramatically
delaying what is often life-saving treatment or quarantine
measures.
About PositiveID
Corporation
PositiveID
Corporation is a life sciences tools and diagnostics company with
an extensive patent portfolio. PositiveID develops biological
detection and diagnostics systems, specializing in the development
of microfluidic systems for the automated preparation of and
performance of biological assays. PositiveID is also a leader in
the mobile technology vehicle market, with a focus on the
laboratory market and homeland security. For more information on
PositiveID, please visit http://www.psidcorp.com, or connect with
PositiveID on Twitter, Facebook or LinkedIn.
On August 24, 2017,
PositiveID Corporation and its wholly-owned subsidiary PositiveID
Diagnostics, Inc. (collectively, the "Seller"), entered into an
Asset Purchase Agreement ("APA") with ExcitePCR Corporation.
Pursuant to the APA, at closing, the Seller will sell and deliver
to ExcitePCR all assets used in connection with the operation of
the FireflyDX technology. For more information on the APA, please
read PositiveID's Form 8-K filed on August 28, 2017, which can be
found here.
Statements about PositiveID's
future expectations, including the likelihood that
FireflyDX could enable faster, more accurate diagnosis at the
point of care or point of need POC/PON; the
likelihood that PositiveID and ExcitePCR are developing
the FireflyDX family of products in both portable and handheld
forms, to provide accurate, rapid pathogen detection using
real-time PCR in less than 30 minutes, with minimally trained
personnel and at a lower cost than existing systems;
constitute "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934, and as that term is defined in the
Private Litigation Reform Act of 1995. Such forward-looking
statements involve risks and uncertainties and are subject to
change at any time, and PositiveID's actual results could differ
materially from expected results. These risks and uncertainties
include, without limitation, the Company's ability to
complete the development, testing
and commercialization of the FireflyDX-Portable and
FireflyDX-Handheld; the Company's ability to target the
professional healthcare market; the Company's ability to raise
capital; the Company's and ExcitePCR's ability to
close the APA; as well as other risks. Additional
information about these and other factors that could affect the
Company's business is set forth in the Company's various filings
with the Securities and Exchange Commission, including those set
forth in the Company's 10-K filed on March 31, 2017, and 10-Qs
filed on November 13, 2017, August 14, 2017,
and May 15, 2017, under the caption "Risk Factors."
The Company undertakes no obligation to update or release any
revisions to these forward-looking statements to reflect events or
circumstances after the date of this statement or to reflect the
occurrence of unanticipated events, except as required by
law.
Contact:
PositiveID
Corporation
Allison
Tomek
(561)
805-8044
atomek@psidcorp.com